Moderna’s approach to developing this vaccine relies on viral RNA rather than the finished virus particle.
Moderna, like other vaccine researchers, has focused its efforts on the Spike protein coronavirus uses to enter cells.
As with any vaccine, the goal with coronavirus is to get the immune system to produce antibodies that can eliminate the virus.
US-based biotech firm Moderna says its initial human vaccine trials have been a success with all patients developing antibodies against the virus.
All current vaccines used in humans use all or part of the target virus to train the immune system, but an RNA vaccine is potentially faster to develop.